# TechnoGenesys

Source: https://onco.cc/companies/technogenesys/  
OnCo record `technogenesys` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TechnoGenesys makes (R)-9b, a tablet that blocks a protein called ACK1 which helps prostate cancer keep using male hormones after standard hormone drugs stop working. It is in a first trial in men with advanced prostate cancer.

## Summary

TechnoGenesys, Inc., of St. Louis, Missouri, is commercialising (R)-9b, which it calls mahatinib, a small-molecule inhibitor of the androgen receptor-interacting tyrosine kinase ACK1 (TNK2). The company says ACK1 inhibition suppresses androgen receptor and AR-V7 expression, that (R)-9b resensitises enzalutamide- and abiraterone-resistant prostate cancer in preclinical work, and that it also promotes CD8 T-cell responses. The PHAROS phase 1 trial (NCT06705686, IND 167907) is the first clinical test of an ACK1 inhibitor, in metastatic castration-resistant prostate cancer. The company also names triple-negative breast and non-small cell lung cancer as later indications. Its first registered cancer trial, NCT06705686, was posted on ClinicalTrials.gov in November 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: St. Louis, MO
- Type: biotech
- Website: https://www.technogenesys.com/

## Notes

- Founding year not stated on the pages read on 29 October 2026.
- The company website is partly an investment pitch, including revenue projections that are not repeated here.
- No financing round is recorded.

## Sources

- Official website: https://www.technogenesys.com/
- About TechnoGenesys: https://www.technogenesys.com/about
- ClinicalTrials.gov: PHAROS phase 1 trial of (R)-9b (NCT06705686): https://clinicaltrials.gov/study/NCT06705686

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)

---
JSON: https://onco.cc/api/v1/entities/technogenesys.json